Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China
Abstract Objectives The study aimed to assess the cost-effectiveness of deucravacitinib versus apremilast for treating moderate-to-severe plaque psoriasis from the Chinese healthcare system’s perspective. Methods The treatment efficacy of deucravacitinib was compared with apremilast using response r...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2025-09-01
|
| Serie: | BMC Health Services Research |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12913-025-13403-3 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|